The ROE as of November 2024 (TTM) for Mustang Bio, Inc. (MBIO) is 429.53%

According to Mustang Bio, Inc.’s latest financial reports and current stock price. The company's current ROE is 429.53%. This represents a change of -125.32% compared to the average of -1696.29% of the last 4 quarters.

Mustang Bio, Inc. (MBIO) Historical ROE (quarterly & annually)

How has MBIO ROE performed in the past?

The mean historical ROE of Mustang Bio, Inc. over the last ten years is -4713.02%. The current 429.53% ROE has changed -109.11% with respect to the historical average. Over the past ten years (40 quarters), MBIO's ROE was at its highest in in the March 2024 quarter at 105.02%. The ROE was at its lowest in in the December 2023 quarter at -7004.88%.

Mustang Bio, Inc. (MBIO) ROE by Quarter and Year

Discovering the peaks and valleys of Mustang Bio, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Mustang Bio, Inc. (MBIO) Average ROE

How has MBIO ROE performed in the past?

The current ROE of Mustang Bio, Inc. (MBIO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Mustang Bio, Inc. (MBIO) ROE vs. Peers

How is MBIO’s ROE compared to its peers?

Mustang Bio, Inc.’s ROE is less than Checkpoint Therapeutics, Inc. (359.97%), less than Reviva Pharmaceuticals Holdings, Inc. (664.92%), greater than Fortress Biotech, Inc. (-240.30%), greater than Kodiak Sciences Inc. (-84.52%), greater than Fortress Biotech, Inc. (-240.30%), greater than Achilles Therapeutics plc (-54.57%), less than Aptose Biosciences Inc. (1.03%), greater than Aditxt, Inc. (-431.38%), greater than NeuroBo Pharmaceuticals, Inc. (-189.12%), greater than Dermata Therapeutics, Inc. (-247.40%), greater than Unicycive Therapeutics, Inc. (-374.14%), greater than Revelation Biosciences, Inc. (-311.33%), greater than Affimed N.V. (-193.85%), greater than Leap Therapeutics, Inc. (-116.24%), greater than Adaptimmune Therapeutics plc (-74.84%), greater than Corvus Pharmaceuticals, Inc. (-167.55%), less than Akari Therapeutics, Plc (550.78%), greater than Salarius Pharmaceuticals, Inc. (-140.30%), greater than Axcella Health Inc. (-620.40%), greater than Magenta Therapeutics, Inc. (-14.27%), greater than Histogen Inc. (-80.69%),

Build a custom stock screener for Mustang Bio, Inc. (MBIO) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Mustang Bio, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Mustang Bio, Inc. (MBIO) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Mustang Bio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.